Pregled bibliografske jedinice broj: 1161390
GLP-1 receptor – Do we really know what we’re looking at?
GLP-1 receptor – Do we really know what we’re looking at? // Acta histochemica, 123 (2021), 5; 151732, 2 doi:10.1016/j.acthis.2021.151732 (međunarodna recenzija, komentar, stručni)
CROSBI ID: 1161390 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
GLP-1 receptor – Do we really know what we’re
looking at?
Autori
Homolak, Jan ; Babić Perhoč, Ana ; Knezović, Ana ; Osmanović Barilar, Jelena ; Šalkovic-Petrišić, Melita
Izvornik
Acta histochemica (0065-1281) 123
(2021), 5;
151732, 2
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, komentar, stručni
Ključne riječi
GLP-1 ; antibodies ; research methodology
Sažetak
We read with great interest a recent comprehensive review covering the knowns and the unknowns of glucagon-like peptide-1 (GLP-1) by McLean et al. (McLean et al., 2020). GLP-1 is best known for its incretin effects first described in the 1980s that provided strong foundations for the development of GLP-1 targeting drugs and revolutionized pharmacotherapy of insulin resistance in the 2000s (Drucker et al., 2017). Nevertheless, as evident from (McLean et al., 2020), we can expect that the glory days of GLP-1 are far from over and that this incretin is going to be even more important for the doctors of tomorrow based on many of its relevant actions, especially in the cardiovascular and central nervous system. A review by McLean et al. (McLean et al., 2020) drew our attention not only because it covers a timely and captivating topic, but because it clearly emphasizes serious limitations and methodological caveats regarding GLP-1 receptor (GLP-1R) expression analysis. Failure to acknowledge methodological caveats either willfully or through ignorance far too often leads to misinterpretation of the results and formation of unjustified conclusions challenging to rectify once they pass under the peer-review radar, and unfortunately – they often do. In this letter, we wish to acknowledge the intention of McLean et al. (McLean et al., 2020) to warn the readers about the methodological drawbacks, especially those regarding the specificity and sensitivity of GLP- 1R antisera and supplement the „Caveats and limitations“ section (McLean et al., 2020) with our own experience and comment regarding bs-1559R anti- GLP-1R rabbit polyclonal antibody.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Jan Homolak
(autor)
Melita Šalković-Petrišić
(autor)
Ana Babić Perhoč
(autor)
Ana Knezović
(autor)
Jelena Osmanović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Arts & Humanities Citation Index (A&HCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE